Ifenprodil is an antagonist at NMDA receptors specific for NR1 and NR2B subunits; it exhibits neuromodulatory, anticancer, anticonvulsant, cognition enhancing, and vasodilatory effects. In cellular and animal models of ovarian cancer, ifenprodil decreases cellular viability and tumor growth. Ifenprodil also inhibits PTZ-induced hippocampal oxidative stress, astrocytosis, and neuron loss. Additionally, this compound reverses motor deficits when co-administered with L-DOPA in Parkinson’s disease models and prevents rapamycin-induced memory impairment. In vivo, ifenprodil also induces mild vasodilation, decreasing blood pressure and increasing heart rate.